Margarida Maia, PhD, science writer —

Treatment with rituximab helps most adults, ages 75 and older, with ANCA-associated vasculitis (AAV) achieve and maintain disease remission, a French study found. However, a higher rate of serious infections and deaths were reported when rituximab was used as an induction therapy, in combination with high doses of glucocorticoids,…

Excess of a particular amino acid, or protein building block, in the blood may make neutrophils — a type of white blood cell that first responds to an infection or injury — more reactive in ANCA-associated vasculitis (AAV) and large-vessel vasculitis, a study has found. The amino acid, called…

People with eosinophilic granulomatosis with polyangiitis (EGPA) are more likely to report a greater range of symptoms than their doctors, a study that drew on patient- and physician-reported databases found, while showing similarities on other points, like relapse frequency. Given the importance of the patient perspective in both research and…

Risk factors for cardiovascular diseases — those related to the heart and blood vessels — are common in people with ANCA-associated vasculitis and lupus nephritis, an autoimmune disease that causes inflammation in the kidneys, according to a study in Singapore. The study, “Cardiovascular risk assessment in lupus nephritis…

Classifying pulmonary manifestations in people with ANCA-associated vasculitis (AAV) with lung symptoms can help predict disease outcomes and determine which patients should receive more intensive treatment, a study from China suggests. For example, patients showing bleeding into the lungs (alveolar hemorrhage) in their computed tomography (CT) scan of the…

Mycophenolate mofetil (MMF), an immunosuppressant, may sustain remission more efficiently than other therapies in ANCA-associated vasculitis (AAV) patients who have kidney symptoms, a review of clinical trials found. The findings showed that, in clinical trials enrolling only patients with kidney involvement, more than 90% were estimated to maintain…

ANCA-associated vasculitis (AAV) may be a rare complication of exposure to COVID-19 proteins, either through infection or vaccination, a report covering two women suggests. Both were diagnosed early and improved with supportive care and immunosuppressive therapy, the researchers noted. “This adverse event appears to be a very rare complication…

Immunoadsorption, a procedure that removes specific antibodies from the blood, may speed remission in patients with ANCA-associated vasculitis (AAV) and serious kidney disease and help more patients attain this outcome, a small study found. The treatment approach also lowered mortality and reduced the risk of kidney failure or death…

Males are not at a greater risk than females of experiencing kidney failure or death due to ANCA-associated vasculitis (AAV), regardless of the kind of kidney damage they have, a study found. These new findings counter the results of a 2018 study that had reported an increased risk of…

Treatment with tofacitinib is well tolerated and effectively induces remission in people with ANCA-associated vasculitis (AAV), while enabling patients to lower their glucocorticoid doses, a small pilot study suggests. These results indicate that tofacitinib may represent a treatment option for active AAV. However, a larger and randomized controlled trial is needed…